Page last updated: 2024-09-03

omega-n-methylarginine and 4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid

omega-n-methylarginine has been researched along with 4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid in 1 studies

Compound Research Comparison

Studies (omega-n-methylarginine)	Trials (omega-n-methylarginine)	Recent Studies (post-2010) (omega-n-methylarginine)	Studies (4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid)	Trials (4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid)	Recent Studies (post-2010) (4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid)
4,411	344	336	10	0	10

Protein Interaction Comparison

Protein	Taxonomy	omega-n-methylarginine (IC50)	4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid (IC50)
Glutamate receptor ionotropic, NMDA 2D	Homo sapiens (human)		2.7
Glutamate receptor ionotropic, NMDA 2C	Homo sapiens (human)		7

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hawker, DD; Jansen Labby, K; Mataka, JJ; Silverman, RB; Trippier, PC	1

Reviews

1 review(s) available for omega-n-methylarginine and 4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl)-4-oxobutanoic acid

Article	Year
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate	2013

Article

Year

Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate

2013